

The world is racing to find safe and effective vaccines against COVID-19. And when we do, these vaccines must be made available to everyone who needs them regardless of nationality or wealth. Not only is this morally right but it is also the fastest way to end the pandemic. So as world leaders line up to make deals for COVID-19 vaccines candidates we want to know: **did this deal move us closer to, or further from, an equitable outcome?**

The Vaccine Access Test provides a framework to answer this question by evaluating deals between companies and countries using three metrics:

- **Prioritized:** Is this deal aligned with global guidelines on prioritizing allocation among at-risk populations?
- **Phased:** Does this deal allow for phased delivery of doses to ensure initial-supply is not monopolized?
- **Published:** Is the contracting processes transparent from start to finish?

Each metric is worth up to 2 points with the potential for 6 points total. [Here is how this deal stacks up.](#)

DEAL SUMMARY

Parties: Novavax and Australia

Date: January 7, 2021

Terms of Agreement: Novavax announced that it has executed an Advance Purchase Agreement with the Commonwealth of Australia for 51 million doses of NVX-CoV2373, Novavax' COVID-19 vaccine candidate. The company aims to deliver initial doses by mid-2021. As part of the agreement, Australia will have the option to purchase up to an additional 10 million doses.

| METRIC | SCORE | RATIONALE |
|---|-------|---|
| Prioritized  | 0 | 51m doses would cover more than Australia's population with a 2-dose regimen, exceeding the 3% initial allocation threshold and the threshold to prioritize the most vulnerable 20% population. |
| Phased  | 1 | Novavax expects the first portion of doses to be available by mid-2021. Australia has the option to purchase additional doses. Ideally, this would allow for other countries to benefit from the initial supply and tier delivery of subsequent supply as it becomes available. |
| Published  | 0 | Australia has not listed details about the terms of deal and pricing online. Novavax has not disclosed their pricing model. |

Total Score: 1 out of 6

This deal does little to ensure the initial supply of vaccines isn't monopolized by Australia. However, it is a step in the right direction to phase delivery to allow for other countries to benefit from the initial supply.

Subsequent deals could be improved by purchasing against global population allocation guidelines. Novavax could also disclose a break-down of how they arrived at their unit price, and what it costs to produce the vaccine. We will also be watching to ensure subsequent doses aren't purchased before other countries have secured deals for portions of the initial supply.

